Oral delivery of nucleic acid-based therapeutics

Therapeutic Delivery

Volumn 3, Issue 2, 2012, Pages 143-145

  Hardee, Gregory E ^a  

^a NONE   (United States)

Author keywords

cost of therapy; nucleic acid based therapeutics; oligonucleotide; oral bioavailability; oral delivery; penetration enhancers

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; NUCLEIC ACID BASE; OLIGONUCLEOTIDE;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84857152325     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.143     Document Type: Review

References (18)

1. Hardee GE, Lindholm MW, Hansen HF et al. Pharmacology, target reduction and drug accumulation after oral feeding of an LNA antisense oligonucleotide directed against apoB-100. Presented at: Arteriosclerosis, Thrombosis and Vascular Biology. San Francisco, CA, USA, April 2010.
2. Aouadi M, Tesz GJ, Nicoloro SM et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458, 1180-1185 (2009).
3. Bennett FC, Swayze E, Geary RS et al. Antisense Oligonucleotide-Based Therapeutics, Gene and Cell Therapy (Second Edition). Marcel Decker Inc., NY, USA, 347-374 (2004).
4. Hardee GE, Tillman LG, Geary RS. Routes and formulations for delivery of antisense oligonucleotides. Stanley TC(Ed). Antisense Drug Technology, Chapter 8. CRC Press, Taylor Francis Group, UK, 217-236 (2006).
5. Tillman L, Geary R, Hardee GE. Oral delivery of antisense oligonucleotides: plasma bioavailability of ISIS 104838 in man. J. Pharm. Sci. 97(1), 225-236 (2008).
6. Patil SD, Rhodes DG, Burgess DJ. DNA-based therapeutics and DNA delivery systems: a comprehensive review. J. Am. Pharm. Sci. 7(1), E61-E77 (2005). (Pubitemid 41554297)
7. Hayashi M, Sakai T, Hasegawa Y et al. Physiological mechanism for enhancement of paracellular drug transport. J. Control. Release Soc. 62, 141-148 (1999). (Pubitemid 29486492)
8. Geary RS, Khatsenko O, Bunker K et al. Absolute bioavailability of 2-O-(2- methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J. Pharmacol. Exp. Ther. 296(3), 898-904 (2001). (Pubitemid 32187363)
9. Nicklin PL, Bayley D, Giddings J et al. Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes. Pharm. Res. 15(4), 583-591 (1998). (Pubitemid 28214952)
10. Salama NN, Eddington ND, Fasano A. Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev. 58, 15-28 (2006)
11. Maher S, Leonard TW, Jacobsen J et al. Safety and efficacy of sodium caprate in promoting drug absorption: from in vitro to the clinic. Adv. Drug Deliv. Rev. 61, 1427-1449 (2009).
12. Tsutsumi K, Li SK, Hymas RV et al. Systematic studies on the paracellular permeation of model permeants and oligonucleotides in the rat small intestine with chenodeoxycholate as enhancer. J. Pharm. Sci. 97(1), 350-367 (2008).
13. Raoof AA, Chiu P, Ramtoola, Z et al. Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J. Pharm. Sci. 93(6), 1431-1439 (2004). (Pubitemid 38725017)
14. Baluom M, Friedman M, Assaf P et al. Synchronized release of sulpiride and sodium decanoate from HPMC matrices: a rational approach to enhance sulpiride absorption in the rat intestine. Pharm. Res. 17, 1071-1076 (2000)
15. Cano-Cebrian MJ, Zornoza T, Granero L et al. Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr. Drug Deliv. 2, 9-22 (2005). (Pubitemid 40590917)
16. Geary RS, Teng CL, Raoof AA et al. Cross-species comparison of the tolerability and effect of absorption enhancer on systemic delivery of antisense oligonucleotides following intra-intestinal administration. Presented at: AAPS Annual Meeting. Indianapolis, IN, USA, 29 October-2 November 2000.
17. Cox AB, Rawlinson LA, Baird AW et al. In vitro interactions between the oral absorption promoter, sodium caprate (C10) and S. typhimurium in rat intestinal ileal mucosae. Pharm. Res. 25(1), 114-122 (2008).
18. Whitehead K, Karr N, Mitragotri S. Safe and effective permeation enhancers for oral drug delivery. Pharm. Res. 25, 1782-1788 (2007).